Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims accurately reflect labeled attributes for Yervoy (ipilimumab) identity, brand name status, mechanism (CTLA-4 blockade), and the melanoma indication. Claims regarding broader lung cancer use, cost, patents, generics, and insurance coverage are not supported by the provided prescribing information.
Category Scores
Accurate Statements
Yervoy is a brand-name medication.
11
Yervoy is a type of immunotherapy.
12.1
Yervoy works by stimulating the immune system to attack cancer cells.
12.1
Yervoy is used to treat melanoma.
1.1
Unsupported Statements
Yervoy is used to treat lung cancer.
Not supported by the provided labeling sections; the claim is not clearly supported as a general lung cancer indication in the supplied label content.
The average cost of Yervoy can range from $10,000 to $20,000 per month, depending on the dosage and treatment regimen.
Cost information is not addressed by the provided prescribing information.
A generic version of Yervoy is not yet available.
Generic status is not discussed in the provided labeling sections.
The patent for Yervoy was filed in 2004.
Patent information is not provided in the supplied labeling sections.
The patent is not set to expire until 2025.
Patent expiration details are not provided in the labeling sections.
Patients who need this medication may have to continue paying high prices for the brand-name version.
No information about pricing or patient cost assistance is provided in the label content.
Insurance coverage for Yervoy is typically only available for patients who meet certain criteria.
No information about insurance coverage criteria is provided in the label content.
Diagnosis affects coverage: Yervoy is typically only covered for patients with certain types of cancer, such as melanoma or lung cancer.
No information about coverage criteria or diagnosis-based coverage is provided in the label content.
Coverage depends on treatment regimen: Insurance plans may cover Yervoy for patients who are receiving it as part of a clinical trial or as a first-line treatment for their cancer.
No information about insurance coverage conditions is provided in the label content.
Patient financial situation can affect coverage; some insurance plans may offer financial assistance or copay programs for patients who are struggling to afford Yervoy.
No information about patient assistance programs in the label content.
Patient assistance programs exist to help patients access their medications at a lower cost.
No information about patient assistance programs is provided in the label content.
Copay cards exist to help patients pay for their medications.
No information about copay programs is provided in the label content.
Financial assistance programs exist to help patients pay for their medications.
No information about financial assistance programs is provided in the label content.
The patent expiration in 2025 could lead to a generic version becoming available in the future.
No patent expiration information is provided in the label content.
Contradictions
Important Omissions
No dosing and administration details are described in the claims; no explicit dosing guidance is evaluated.
Importance:
Moderate
No discussion of contraindications, boxed warnings, warnings and precautions, drug interactions, use in specific populations, adverse reactions, monitoring recommendations, or storage/handling is present in the evaluated claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
No safety claims or adverse event risks are asserted in the evaluated statements; primary focus is on identity, mechanism, and a melanoma indication.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some claims (lung cancer as a broad indication, cost, patent/generic status, insurance coverage) are not supported by the label content provided.
Suggested Improvement
Restrict claims to label-supported indications and identity; avoid extrapolations about cost, patent status, generic availability, and insurance coverage without corresponding label data; provide explicit dosing and safety-related details if addressing those areas.